LifeVantage (NASDAQ:LFVN) Issues Earnings Results, Beats Expectations By $0.08 EPS

LifeVantage (NASDAQ:LFVN) released its earnings results on Wednesday. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.08, Zacks reports. LifeVantage had a return on equity of 29.24% and a net margin of 2.11%.

LifeVantage Stock Performance

NASDAQ LFVN traded down $1.00 during trading hours on Wednesday, reaching $22.74. 486,894 shares of the company’s stock were exchanged, compared to its average volume of 270,076. LifeVantage has a one year low of $5.22 and a one year high of $27.38. The company’s 50-day moving average is $18.97 and its two-hundred day moving average is $13.59. The company has a market capitalization of $284.70 million, a price-to-earnings ratio of 71.06 and a beta of 0.84.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on LFVN shares. Lake Street Capital began coverage on shares of LifeVantage in a report on Thursday, December 19th. They set a “buy” rating and a $26.00 price objective for the company. Craig Hallum initiated coverage on shares of LifeVantage in a research report on Tuesday, January 14th. They issued a “buy” rating and a $35.00 price objective for the company.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.